This Article Full Text Full Text (PDF) All Versions of this Article: 36/2/360    most recent 01.STR.0000153002.56324.8cv1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, P. S.J. Articles by Kalra, L. Search for Related Content PubMed PubMed Citation Articles by Miller, P. S.J. Articles by Kalra, L. Related Collections Anticoagulants Health policy and outcome research Embolic stroke

(Stroke. 2005;36:360.)
© 2005 American Heart Association, Inc.

Comments, Opinions, and Reviews

Are Cost Benefits of Anticoagulation for Stroke Prevention in Atrial Fibrillation Underestimated?

From AstraZeneca (P.S.J.M.), Alderley Park, UK; AstraZeneca R&D Lund (F.L.A.), Sweden; Guy’s, King’s & St Thomas’ School of Medicine (L.K), London UK.

Correspondence to Paul Miller, AstraZeneca, HEOR/Clinical Science, Parklands FE2 D/4, Alderley Park, SK10 4TG UK. E-mail Paul.Miller3{at}astrazeneca.com

Background and Purpose— Stroke outcomes in patients with atrial fibrillation (AF) tend to be worse than those in patients without AF. The objective of this study was to evaluate whether the cost benefits of anticoagulation for stroke prevention in AF may currently be underestimated by existing economic models that do not distinguish between different stroke outcomes.

Methods— A literature review was conducted in 3 areas: (1) studies comparing stroke outcomes in AF and non-AF patients; (2) studies providing long-term cost of stroke estimates; and (3) studies modeling the cost-effectiveness of anticoagulation with a vitamin K antagonist (eg, warfarin) in AF patients.

Results— There is considerable evidence that stroke in AF patients has a worse outcome than in patients without AF, including higher mortality, severity, and recurrence rates, and greater functional impairment and dependency. Estimates of the long-term cost of stroke of different severities were between US $24 991 for a mild stroke over 5 years and US $142 251 for a major ischemic stroke over a lifetime (2004 prices). The cost of a severe ischemic stroke may typically be 3-times that of mild stroke. However, cost-effectiveness models for anticoagulation in patients with AF have used average (not AF-specific) cost-of-stroke data, and most have used stroke severity distributions derived from clinical trials, which may differ from those in clinical practice.

Conclusions— Existing economic models underestimate the cost benefits of anticoagulation for stroke prevention because they do not adjust for poorer outcomes associated with cardioembolic strokes.

Key Words: anticoagulants • arrhythmia • cost-benefit analysis • primary prevention • stroke

This article has been cited by other articles:

				M. D. Caldwell, R. L. Berg, K. Q. Zhang, I. Glurich, J. R. Schmelzer, S. H. Yale, H. J. Vidaillet, and J. K. Burmester Evaluation of Genetic Factors for Warfarin Dose Prediction Clin. Med. Res., March 1, 2007; 5(1): 8 - 16. [Abstract] [Full Text] [PDF]

				P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54. [Abstract] [Full Text] [PDF]